Five-year survival analysis of surgically resected gastric cancer cases in Japan: a retrospective analysis of more than 100,000 patients from the nationwide registry of the Japanese Gastric Cancer Association (2001-2007)
Five-year survival analysis of surgically resected gastric cancer cases in Japan: a retrospective analysis of more than 100,000 patients from the nationwide registry of the Japanese Gastric Cancer Association (2001-2007)
复制标题
DOI：
10.1007/s10120-017-0716-7
复制
发表时间：
2018-01-01
期刊：
影响因子：
7.4
通讯作者：
Nashimoto, Atsushi
中科院分区：
文献类型：
--
作者：
Katai, Hitoshi;Ishikawa, Takashi;Nashimoto, Atsushi
背景本研究的目的是从日本胃癌协会的全国登记资料中调查胃癌手术切除的肿瘤特征、手术细节和生存分布。方法对2001-2007年间118,367例接受手术切除的原发胃癌患者的资料进行生存分析。结果患者的中位年龄为67岁。病理分期(日本胃癌协会)IA、IB、II、IIIA、IIIB和IV期患者的比例分别为44.0%、14.7%、11.7%、9.5%、5.0%和12.4%。术后30d内死亡率为0.5%。在118,367例接受切除术的患者中，5年总存活率为71.1%。病理分期IA、IB、II、IIIA、IIIB和IV期患者的5年总生存率分别为91.5%、83.6%、70.6%、53.6%、34.8%和16.4%。PT1(黏膜)病患者经淋巴结清扫7号(d1+α)、清扫d1+淋巴结站nos后5年的疾病特异性生存率。7、8、9(D1+beta)组和D2组分别为99.4%、99.6%和99.1%。PT1(粘膜下层)疾病患者在接受D1+α、D1+β和D2淋巴清扫后的5年疾病特异性生存率分别为97.3%、98.1%和96.9%。结论对10万多名患者的详细分析显示了日本胃癌治疗结果的最新趋势，为世界各地的医学界提供了基线信息。
Background The aim of this retrospective study was to investigate the tumor characteristics, surgical details, and survival distribution of surgically resected cases of gastric cancer from the nationwide registry of the Japanese Gastric Cancer Association.Methods Data from 118,367 patients with primary gastric carcinoma who underwent resection between 2001 and 2007 were included in the survival analyses. The 5-year survival rates were calculated for various subsets of prognostic factors.Results The median age of the patients was 67 years. The proportions of patients with pathological stage (Japanese Gastric Cancer Association) IA, IB, II, IIIA, IIIB, and IV disease were 44.0%, 14.7%, 11.7%, 9.5%, 5.0%, and 12.4% respectively. The death rate within 30 days of operation was 0.5%. The 5-year overall survival rate in the 118,367 patients who were treated by resection was 71.1%. The 5-year overall survival rates of patients with pathological stage IA, IB, II, IIIA, IIIB, and IV disease were 91.5%, 83.6%, 70.6%, 53.6%, 34.8%, and 16.4% respectively. The 5-year disease-specific survival rates in the patients with pT1 (mucosa) disease after D1+ dissection of lymph node station no. 7 (D1 + alpha), D1+ dissection of lymph node station nos. 7, 8, and 9 (D1+ beta), and D2 lymphadenectomy were 99.4%, 99.6%, and 99.1% respectively. The 5-year disease-specific survival rates in the patients with pT1 (submucosa) disease after D1 + alpha, D1 + beta, and D2 lymphadenectomy were 97.3%, 98.1%, and 96.9% respectively.Conclusion Detailed analyses of the data from more than 100,000 patients show the recent trends of the outcomes of gastric cancer treatment in Japan and provide baseline information for use by medical communities around world.